Risk factors for mortality in patients with carbapenem-resistant acinetobacter baumannii bacteremia: Impact of appropriate antimicrobial therapy

Journal of Korean Medical Science

Volumn 27, Issue 5, 2012, Pages 471-475

  Kim, Youn Jeong ^a   Kim, Sang I ^a   Hong, Kyung Wook ^a   Kim, Yang Ree ^a   Park, Yeon Joon ^a   Kang, Moon Won ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Acinetobacter baumannii; Carbapenem resistance; Mortality; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SEPTIC SHOCK; SURVIVAL RATE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; APACHE; CARBAPENEMS; DIABETES COMPLICATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 84862902944     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.5.471     Document Type: Article

References (23)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-84.
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51.
3. Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect 2003; 54: 39-45.
4. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 2005; 60: 256-60.
5. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18: 306-13.
6. Daniels TL, Deppen S, Arbogast PG, Griffin MR, Schaffner W, Talbot TR. Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in surgical intensive care units. Infect Control Hosp Epidemiol 2008; 29: 1080-3.
7. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009; 15: 1325-7.
8. Robenshtok E, Paul M, Leibovici L, Fraser A, Pitlik S, Ostfeld I, Samra Z, Perez S, Lev B, Weinberger M. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes. J Hosp Infect 2006; 64: 282-7.
9. Jerassy Z, Yinnon AM, Mazouz-Cohen S, Benenson S, Schlesinger Y, Rudensky B, Raveh D. Prospective hospital-wide studies of 505 patients with nosocomial bacteraemia in 1997 and 2002. J Hosp Infect 2006; 62: 230-6.
10. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007; 28: 293-8.
11. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115: 529-35.
12. Erbay A, Idil A, Gözel MG, Mumcuoǧlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009; 34: 575-9.
13. Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, Choi SH, Woo JH, Kim YS. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci 2011; 26: 325-31.
14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing Informational Supplement M100-S16. Wayne: Clinical and Laboratory Standards Institute, 2008.
16. Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603.
17. Tilley PA, Roberts FJ. Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis 1994; 18: 896-900.
18. Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38: 127-36.
19. Joung MK, Kwon KT, Kang CI, Cheong HS, Rhee JY, Jung DS, Chung SM, Lee JA, Moon SY, Ko KS, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect 2010; 61: 212-8.
20. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, Garcia-Curiel A, Jiménez-Jiménez FJ. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31: 649-55.
21. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59: 525-30.
22. Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, Leu HS, Chiang PC. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010; 5: e9947.
23. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drugresistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64: 7-15.